Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Cambridge Cognition wins contract for a pivotal schizophrenia clinical trial

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for a further sizeable schizophrenia trial with an existing customer. Cambridge Cognition has been selected again to provide its proprietary gold standard digital cognitive assessments, CANTABTM, and specialist study management services. The latest contract is worth more than £600,000 to the Company over three years.

Patients with schizophrenia often experience cognitive impairment, with deficits observed in memory, attention and executive function. CANTABTM cognitive assessments can measure these distinct processes with a high degree of sensitivity and so offers a valuable efficacy endpoint for the novel pharmaceutical being investigated.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"We are delighted with the enduring partnership we have formed with this client and the award of a further order for digital technology solutions from them. This is also great news for us as our strategy is to broaden our offering and expand into more therapeutic areas. Demonstrating the value of digital cognitive assessments in schizophrenia drug development could provide for many more similar opportunities in the future."

For further information, contact:

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com